Program
infigratinib
Also written as “Infigratinib”, “BGJ398” and “infigratinib 0.128 mg/kg/day”.
Its studies are mostly in Achondroplasia · Mucopolysaccharidosis IV · Stomach Neoplasms · Cholangiocarcinoma · Urinary Bladder Neoplasms, led by 5 companies.
Drug pageInfigratinib: every studyMany companies study it; this page follows only the 17 they lead. All 30 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BridgeBio | 83 open or running | phase 3since Dec 10, 2018 | May 12, 2014 | Jan 2027phase 3 · NCT06873035 |
| Novartisits history only | 50 open or running | phase 2since Oct 28, 2013 | Oct 27, 2009 | none ahead |
| LianBioits history only | 20 open or running | phase 2since Jul 28, 2021 | Jul 28, 2021 | none ahead |
| Helsinn Healthcareits history only | 10 open or running | phase 2since Jan 12, 2022 | Jan 12, 2022 | none ahead |
| Pfizerits history only | 10 open or running | phase 2since Apr 28, 2014 | Apr 28, 2014 | none ahead |
Also a collaborator on its studies: Labcorp Corporation of America.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of BridgeBio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 12, 2014First study: phase 2 study in CholangiocarcinomaFirst studyNCT02150967 · 143 enrolled · United States, Belgium, Germany and more
- Dec 10, 2018Phase 3 study in CholangiocarcinomaNCT03773302 · 48 enrolled · United States, Australia, Belgium and more
- Dec 2, 2019Phase 3 study in Upper Tract Urothelial CarcinomasNCT04197986 · 39 enrolled · United States, Belgium, Bulgaria and more
- Jan 29, 2020Phase 2 study in AchondroplasiaNCT04265651 · 84 enrolled · United States, Australia, Canada and more
- Nov 22, 2021Phase 2 study in AchondroplasiaNCT05145010 · 325 planned · United States, Argentina, Australia and more
- Nov 29, 2023Phase 3 study in AchondroplasiaNCT06164951 · 114 enrolled · United States, Argentina, Australia and more
- Feb 18, 2025Phase 3 study in HypochondroplasiaNCT06873035 · 24 planned · United States, Australia, Canada and more
- Jan 19, 2026Phase 2 study in HypochondroplasiaNCT07393373 · 135 planned · United States, Australia, Canada and more
Ahead
- Jan 2027Primary completion: phase 3 study in HypochondroplasiaNCT06873035
- Dec 1, 2031Primary completion: phase 2 study in AchondroplasiaNCT05145010
- May 31, 2036Primary completion: phase 2 study in HypochondroplasiaNCT07393373
TargetBeta
“Fibroblast growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| futibatinibrule | Otsuka | phase 3 | 10 |
Studies
All 8 BridgeBio leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07393373Hypochondroplasia · United States, Australia, Canada and more | 2 | By invitation | May 31, 2036 | 135 |
| NCT06873035Hypochondroplasia · United States, Australia, Canada and more | 3 | By invitation | Jan 2027 | 24 |
| NCT06164951Achondroplasia · United States, Argentina, Australia and more | 3 | Completed | Dec 18, 2025 | 114 |
| NCT05145010Achondroplasia · United States, Argentina, Australia and more | 2 | By invitation | Dec 1, 2031 | 325 |
| NCT04265651Achondroplasia · United States, Australia, Canada and more | 2 | Completed | Oct 21, 2024 | 84 |
| NCT04197986Upper Tract Urothelial Carcinomas · United States, Belgium, Bulgaria and more | 3 | Terminated | Feb 28, 2023 | 39 |
| NCT03773302Cholangiocarcinoma · United States, Australia, Belgium and more | 3 | Terminated | Mar 2, 2023 | 48 |
| NCT02150967Cholangiocarcinoma · United States, Belgium, Germany and more | 2 | Terminated | Mar 1, 2021 | 143 |
How it is read
Names in the registry
- “Infigratinib”, 7 entries
- “BGJ398”, 7 entries
- “infigratinib 0.128 mg/kg/day”, 1 entry
- “infigratinib 0.25 mg/kg/day”, 1 entry
- “Infigratinib 0.25 mg/kg/day”, 1 entry
Conditions, from the studies’ own filings
- Achondroplasia, 3 studies
- Mucopolysaccharidosis IV, 2 studies
- Stomach Neoplasms, 2 studies
- Cholangiocarcinoma, 2 studies
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.